Pfizer says experimental breast cancer drug cuts risk of disease worsening in mid-stage trial

March 17 (Reuters) - Pfizer said on Tuesday its experimental combination reduced the risk of disease progression or death by ...

Pfizer’s oral CDK4 inhibitor shows promise in second-line breast cancer

Pfizer’s CDK4 inhibitor, atirmociclib, is already being investigated in a Phase III trial as a first-line therapy.

Pfizer succeeds in mid-stage trial for breast cancer therapy

Pfizer (PFE) announced on Tuesday that its investigational breast cancer therapy, atirmociclib, as part of a combination regimen, reached the main goal in a mid-stage trial for certain patients with ...

Pfizer posts late-stage trial win for Talzenna plus Xtandi in new prostate cancer indication

Pfizer (PFE) stock is in focus as Xtandi, marketed with Astellas (ALPMF), and cancer drug Talzenna succeed in a Phase 3 trial for prostate cancer. Read more here.

Pfizer Phase 2 Atirmociclib Study Meets Primary Endpoint

Pfizer on Tuesday said the randomized Phase 2 study met its primary endpoint, showing a 40% reduction in the risk of disease progression or death with a manageable safety profile.

Pfizer Reports Positive Results in Prostate Cancer Study

Pfizer reported positive topline results in its phase three study of talazoparib in combination with enzalutamide to treat metastatic hormone-sensitive prostate cancer. The study met its primary ...

Keytruda and Padcev could become cancer’s power couple

The two blockbusters have made a big difference in bladder cancer survival, but will their chemistry hold up when tested in other types?